1. Home
  2. LUCD vs STXS Comparison

LUCD vs STXS Comparison

Compare LUCD & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

HOLD

Current Price

$1.27

Market Cap

183.5M

Sector

Health Care

ML Signal

HOLD

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$1.82

Market Cap

201.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCD
STXS
Founded
2018
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.5M
201.6M
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
LUCD
STXS
Price
$1.27
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$3.94
$4.00
AVG Volume (30 Days)
659.4K
385.7K
Earning Date
03-26-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
16.67
16.67
EPS
N/A
N/A
Revenue
$4,346,000.00
$29,346,617.00
Revenue This Year
$7.69
$34.08
Revenue Next Year
$155.47
$35.18
P/E Ratio
N/A
N/A
Revenue Growth
79.00
N/A
52 Week Low
$0.95
$1.54
52 Week High
$1.80
$3.59

Technical Indicators

Market Signals
Indicator
LUCD
STXS
Relative Strength Index (RSI) 40.44 33.27
Support Level $1.01 N/A
Resistance Level $1.52 $2.52
Average True Range (ATR) 0.06 0.12
MACD -0.02 -0.02
Stochastic Oscillator 14.38 14.05

Price Performance

Historical Comparison
LUCD
STXS

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Share on Social Networks: